294
Participants
Start Date
November 29, 2021
Primary Completion Date
July 20, 2022
Study Completion Date
August 3, 2022
AD109
Oral administration at bedtime
AD504
Oral administration at bedtime
Atomoxetine Hydrochloride
Oral administration at bedtime
Placebo
Oral administration at bedtime
Clinilabs, New York
Brian Abaluck, LLC, Malvern
The Center for Sleep & Wake Disorders, Chevy Chase
Sleep Disorders Centers of the Mid-Atlantic (SDCMA), Glen Burnie
Coastal Carolina Health Care, P.A., New Bern
Bogan Sleep Consultants LLC, Columbia
Velocity Clinical Research, Greenville
NeuroTrials Research, Inc., Atlanta
Research Centers of America -- Hollywood, Hollywood
Sleep Medicine Specialists of South Florida, Miami
Teradan Clinical Trials, Brandon
CTI Clinical Research Center, Cincinnati
Intrepid Research, Cincinnati
Sleep and Attention Disorders Institute, Sterling Heights
Henry Ford Hospital, Detroit
Minnesota Lung Center / Minnesota Sleep Institute, Woodbury
Chicago Research Center, Chicago
St. Luke's Hospital Sleep Medicine, Chesterfield
Clayton Sleep Institute, Maplewood
FutureSearch Trials of Neurology, Austin
Delta Waves, Colorado Springs
Santa Monica Clinical Trials, Los Angeles
Pacific Research Network, San Diego
SDS Clinical Trials, Inc., Santa Ana
Neurocare, Newton
Lead Sponsor
Apnimed
INDUSTRY